Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101

[1]  T. Powles,et al.  Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis. , 2021, Journal of geriatric oncology.

[2]  F. Donskov,et al.  Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity. , 2020, Journal of geriatric oncology.

[3]  S. Culine,et al.  Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis , 2020, Drugs & Aging.

[4]  G. Banna,et al.  A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. , 2020, Critical reviews in oncology/hematology.

[5]  C. Stief,et al.  Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers. , 2020, Journal of geriatric oncology.

[6]  R. Motzer,et al.  Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Roger B. Davis,et al.  Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma. , 2019, Clinical genitourinary cancer.

[8]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[9]  L. Livi,et al.  Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy , 2018, PloS one.

[10]  B. Rini,et al.  Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study , 2017, Cancer science.

[11]  J. Haanen,et al.  Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer , 2017, Angiogenesis.

[12]  R. Motzer,et al.  Systemic Therapy for Metastatic Renal-Cell Carcinoma. , 2017, The New England journal of medicine.

[13]  B. Rini,et al.  Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study , 2016, Japanese journal of clinical oncology.

[14]  R. Motzer,et al.  Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma , 2016, Nature Reviews Urology.

[15]  J. Schlom,et al.  Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells , 2015, Cancer Immunology Research.

[16]  H. Akaza,et al.  Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma , 2014, Cancer science.

[17]  N. Vogelzang,et al.  Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. , 2013, The Lancet. Oncology.

[18]  E. Jonasch,et al.  Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. , 2013, The Lancet. Oncology.

[19]  H. Akaza,et al.  Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial , 2013, Japanese journal of clinical oncology.

[20]  R. Bukowski.  Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma , 2012, Front. Oncol..

[21]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[22]  H. Akaza,et al.  Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. , 2011, European journal of cancer.

[23]  P. O'Connor,et al.  Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 , 2008, Clinical Cancer Research.